Spartan acquires 17 supermarkets and 15 pharmacies from VG’s
GRAND RAPIDS, Mich. Spartan Stores has finished its acquisition of 17 supermarkets and 15 pharmacies from VG’s Food Center and VG’s Pharmacy, the grocery distributor announced Monday.
VG’s is based in Fenton, Mich., and is Spartan’s largest independent distribution customer. Because of that, Spartan expects the acquisition to increase annual retail segment sales by about $300 million, with annual consolidated sales increasing by around $150 million.
“We are very pleased to complete the acquisition of VG’s retail stores,” Spartan president and chief executive officer Dennis Eidson said in a statement. “This transaction provides us with the opportunity to sustain our long-term performance improvement record, capture additional operational synergies and serve communities in key Michigan markets where we had no retail presence.”
KV subsidiary hydromorphone hydrochloride tablets
ROCKVILLE, Md. A subsidiary of KV Pharmaceutical has recalled a lot of hydromorphone hydrochloride 2 mg tablets due to the possibility of oversized tablets, the Food and Drug Administration announced Tuesday.
Ethex Corporation and the FDA have notified healthcare professionals of the recall. The FDA that the oversized pills may lead to improper dosage, thus increasing the risk of adverse side affects associated with the drug, including difficulty breathing, low blood pressure and sedation.
The recalled tablets are round and blue, with a script “E” on one side and a “2” on the other. The recalled lot number is 90219, with an expiration date of March 2010 and the NDC number 58177-0620-04.
The tablets are a generic version of Purdue Pharma?s Dilaudid and used to treat severe pain.
Eli Lilly signs $497 million deal for dirucotide
NEW YORK Eli Lilly & Co. may get some relief from its drying pool of patent-protected drugs.
The Indianapolis drug maker has signed an agreement worth $497 million with biotech firm BioMS Medical Corp. for the drug dirucotide, a treatment for multiple sclerosis.
Expiring patents on Lilly drugs place nearly $10 billion of the company’s sales under threat.